SSCI

What SSCI does

SSCI operates as Curia, a global Contract Development and Manufacturing Organization (CDMO) headquartered in West Lafayette, Indiana, founded in 1991. Note: the firmographics "short_description" characterizes SSCI as a provider of professional development short courses to the pharmaceutical industry; this is inconsistent with the far more detailed company-level data, which consistently describes SSCI/Curia as a full-spectrum CDMO with discovery, development, and commercial manufacturing operations. The detailed source material is treated as authoritative.

Curia's core offering is an integrated small molecule and biologics platform spanning the drug development continuum. Small molecule services include discovery (assay development, cell-based assays, computer-aided drug design, DMPK, medicinal chemistry, integrated drug discovery), development and manufacturing (API manufacturing, chemical process R&D, fermentation, flow chemistry, GMP controlled substances, high-potency APIs, sterile API manufacturing, industrial chromatography, steroids and hormones), and a fine chemicals catalog (4-FPBA, Gemagique AMPS polymers, oxa acids, T3P reagent, VPA). Biologics capabilities cover antibody discovery and engineering, mammalian and baculovirus expression systems, mRNA process development and GMP manufacturing, LNP formulation, and biorepository services. Sterile drug product (formulation, clinical and commercial manufacturing) and analytical testing (batch release, method validation, solid state chemistry) round out the portfolio. Specialized infrastructure includes a $4 million-upgraded aseptic manufacturing facility in Valladolid, Spain, aligned with EU GMP Annex 1 standards.

The business model is B2B enterprise CDMO with three revenue streams: fee-for-service drug discovery projects, long-term managed-service API and drug product manufacturing contracts, and a catalog of generic APIs sold on a transaction basis. Go-to-market is direct enterprise sales targeting pharmaceutical and biotech clients globally, supplemented by industry events, white papers, fact sheets, and a LinkedIn presence. Customers are segmented horizontally across pharma (primary) and biotech (secondary), with sub-brands organized around Small Molecule, Generic APIs, Biologics, and Sterile Drug Product. Pricing is custom quote-based and not publicly disclosed. Legal entity is Curia Global, Inc., incorporated in the USA; ownership structure, revenue, and funding history are not disclosed in the source data.

Name

SSCI

Legal name

Curia Global, Inc.

Website

https://ssci-inc.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

101–250 employees

Short description

SSCI, operating as Curia, is a U.S.-headquartered global CDMO providing integrated small molecule and biologics discovery, development, and commercial manufacturing services to pharmaceutical and biotechnology companies.

Ownership category

akta.pro rank

Product category

Contract Pharmaceutical Development and Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Contract pharmaceutical manufacturing
• Drug discovery services
• API manufacturing services
• Sterile drug product manufacturing
• Biologics development services

Headquarters

HQ city

West Lafayette

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Drug Discovery Services: Fee-for-service model for discovery biology, medicinal chemistry, DMPK, and bioanalytical services delivered through project-based contracts
2. Contract Manufacturing (API & Drug Product): Long-term manufacturing contracts for active pharmaceutical ingredients and sterile drug products, typically multi-year agreements with pharmaceutical companies
3. Generic APIs: Sales of generic active pharmaceutical ingredients through catalog offerings

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

SSCI, operating as Curia (legal name Curia Global, Inc.), is a Contract Development and Manufacturing Organization (CDMO) providing integrated pharmaceutical services across the drug development continuum. The portfolio spans small molecule discovery, development and manufacturing; biologics discovery, development and manufacturing (including mRNA and antibodies); sterile drug product manufacturing; generic APIs; fine chemicals; and analytical testing services. The company serves pharmaceutical and biotech companies worldwide with phase-appropriate capabilities from early-stage research through commercial manufacturing.

Product overview

SSCI (operating as Curia) is a Contract Development and Manufacturing Organization (CDMO) offering integrated pharmaceutical services across the drug development continuum. The portfolio includes Small Molecule services (Discovery, Development & Manufacturing, and Fine Chemicals), Generic APIs, Biologics (Discovery, Development, and Manufacturing), Sterile Drug Product services, and Analytical Testing Services. The company provides end-to-end capabilities from early-stage research through commercial manufacturing, with specialized expertise in high potency compounds, sterile manufacturing, mRNA, and controlled substances.

Differentiator

Problem solved

Functional benefit

Brands

• Curia Small Molecule: Integrated small molecule drug discovery, development, and manufacturing services including API manufacturing, chemical process R&D, fermentation, flow chemistry, GMP controlled substances, high potency, sterile API manufacturing, industrial chromatography, steroids and hormones, and fine chemicals.
• Curia Generic APIs
• Curia Biologics
• Curia Sterile Drug Product
• Gemagique® AMPS Polymers

Products and services

• Small Molecule Drug Discovery Integrated drug discovery services covering assay development and screening, cell-based assays, computer-aided drug design (CADD), custom synthesis, DMPK, in vitro biology, medicinal chemistry, protein expression and analysis, structural biology, and end-to-end integrated discovery programs. Serves pharmaceutical and biotech companies seeking hit identification through candidate selection.
• Small Molecule Development & Manufacturing Small molecule API development and manufacturing services including API manufacturing, chemical process R&D, fermentation, flow chemistry, GMP controlled substance handling, high potency manufacturing, sterile API manufacturing, industrial chromatography, steroids and hormones, and regulatory support. Serves pharmaceutical companies requiring clinical and commercial API supply.
• Generic APIs Catalog of generic active pharmaceutical ingredients, specialty products, and intellectual property services sold to pharmaceutical customers seeking off-patent API supply.
• Biologics Discovery Biologics discovery services including antibody discovery and engineering, antibody developability analysis, molecular biology, recombinant antibody and protein production, cell engineering, bioanalytical assays, and biological and functional assays. Targets biotech and pharmaceutical companies developing antibody and protein therapeutics.
• Biologics Development

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature12 records

Scale indicators2 records

Expansion highlights5 records

Direct peers

• Recipharm: European CDMO focused on small molecule APIs, sterile injectables, and drug product. Comparable in API manufacturing, sterile capabilities, and CDMO services to European pharma clients.
• Catalent: Large global CDMO offering integrated small molecule, biologics, and sterile fill-finish services. Directly comparable across API manufacturing, biologics, and drug product services to SSCI/Curia's portfolio.
• Piramal Pharma Solutions: India-headquartered CDMO with strengths in API manufacturing, antibody-drug conjugates, and sterile injectables. Comparable integrated CDMO offering with high-potency and complex chemistry focus.
• Aenova: European CDMO focused on solid dosage forms, sterile liquids, and semi-solids. Comparable drug product manufacturing capabilities, particularly in sterile and complex formulations.
• Samsung Biologics: Major biologics-focused CDMO with large-scale mammalian and mRNA manufacturing capacity. Directly competes in biologics CDMO and increasingly in mRNA, an area SSCI/Curia also serves.
• Charles River Laboratories: CRO/CDMO providing discovery biology, safety assessment, and biologics manufacturing services. Comparable across early-stage discovery, biologics CDMO, and adjacent research services.
• Siegfried Holding: Swiss CDMO providing small molecule API and drug product manufacturing services. Comparable in small molecule API, sterile manufacturing, and CDMO service model.
• WuXi STA: China-based integrated CDMO with strong small molecule API and drug product capabilities. Comparable breadth across small molecule discovery, API manufacturing, and drug product services.
• Lonza: World's largest CDMO with deep capabilities across small molecule APIs, biologics manufacturing, and cell & gene therapy. Comparable integrated offering spanning discovery through commercial manufacturing.

Broad incumbents

• Thermo Fisher Scientific (Patheon): Through its Patheon CDMO business and broader pharma services, Thermo Fisher offers integrated small molecule and biologics manufacturing at scale. Competitor in commercial-scale CDMO services within a much larger diversified life sciences platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/curia-cdmo

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SSCI